It is time to consider third-line options in antiretroviral-experienced paediatric patients?

SUNScholar Research Repository

Show simple item record Van Zyl, Gert U. Rabie, Helena Nuttall, James J. Cotton, Mark F. 2011-12-14T13:54:33Z 2011-12-14T13:54:33Z 2011-11
dc.identifier.citation Van Zyl, G. U., Rabie, H. Nuttall, J. & Cotton, M. F. 2011. It is time to consider third-line options in antiretroviral-experienced paediatric patients?. Journal of the International AIDS Society. 14(1):55 en_ZA
dc.description The original publication is available at
dc.description.abstract Abstract Background The historic use of full-dose ritonavir as part of an unboosted protease inhibitor (PI)-based antiretroviral therapy regimen in some South African children contributes to the frequent accumulation of major PI resistance mutations. Methods In order to describe the prevalence of major PI resistance in children failing antiretroviral therapy and to investigate the clinical, immunological and virological outcomes in children with PI resistance, we conducted a cross-sectional study, with a nested case series, following up those children with major PI resistance. The setting was public health sector antiretroviral clinics in the Western Cape province of South Africa, and the subjects were children failing antiretroviral therapy. The following outcome measures were investigated: CD4 count, viral load and resistance mutations. Results Fourteen (17%) of 82 patients, referred from tertiary hospitals, had major PI resistance. All these patients were exposed to regimens that included ritonavir as a single PI. Immune reconstitution and clinical benefit were achieved when using a lopinavir/ritonavir-based treatment regimen in these children with prior PI resistance. At first HIV-1 viral load follow up after initial resistance testing (n = 11), only one patient had a viral load of less than 400 copies/ml; at a subsequent follow up (n = 9), the viral loads of five patients were less than 400 copies/ml. Patients retained on LPV/r had lower viral loads than those switched to a non-nucleoside reverse transcriptase inhibitor (NNRTI). However, two of three patients with follow-up resistance tests accumulated additional PI resistance. Conclusions In children with pre-existing PI resistance, although initially effective, the long-term durability of a lopinavir/ritonavir-based treatment regimen can be compromised by the accumulation of resistance mutations. Furthermore, a second-line NNRTI regimen is often not durable in these patients. As genotypic resistance testing and third-line treatment regimens are costly and limited in availability, we propose eligibility criteria to identify patients with high risk for resistance and guidance on drug selection for children who would benefit from third-line therapy. en_ZA
dc.description.sponsorship South African Department of Health, Comprehensive Care Management and Treatment grant
dc.format.extent 8 p. : ill.
dc.language.iso en_ZA en_ZA
dc.publisher BioMed Central en_ZA
dc.subject Protease Inhibitor resistance mutations en_ZA
dc.subject Protease inhibitors -- Immunological aspects en_ZA
dc.subject HIV-positive children -- Antiretroviral therapy -- Testing en_ZA
dc.subject HIV/Aids -- Chemotherapy en_ZA
dc.subject HIV-positive children -- Treatment -- South Africa en_ZA
dc.subject Drug resistance -- HIV-positve children -- South Africa en_ZA
dc.title It is time to consider third-line options in antiretroviral-experienced paediatric patients? en_ZA
dc.type Article en_ZA 2011-12-02T06:17:14Z
dc.description.version Peer Reviewed en_ZA
dc.language.rfc3066 en
dc.rights.holder van Zyl et al.; licensee BioMed Central Ltd. en_ZA
 Find Full text

Files in this item

This item appears in the following Collection(s)

Show simple item record